首页 > 用药指导 > 文章详情

Tepezza一年需要多少钱

发布时间:2023-09-17 14:57:00 阅读:109 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

Tepezza

Tepezza 生产厂家:美国Horizon Therapeutics(HZNP) 地平线治疗 功能主治:治疗甲状腺眼病的新型药物,改善患者眼球突出 用法用量:用法用量  Tepezza的推荐剂量是初始剂量为10mg/kg的静脉输注,然后每三周静脉输注20mg/kg,再输注7次。
查看详情
  Tepezza is administered intravenously over a period of three to four months. During this time, patients receive a total of eight infusions, with each infusion being given every three weeks. The cost of a single infusion of Tepezza is approximately $14,900, resulting in a total cost of approximately $119,200 for the entire course of treatment.
  In addition to the cost of the drug itself, patients will also need to consider the expenses associated with visiting a healthcare facility for the infusions. These costs may include consultation fees, facility fees, and additional charges for nursing care. The amount of money spent on these ancillary services can vary depending on the location and healthcare provider. On average, patients may need to allocate an additional $10,000 for these expenses.
Tepezza  Furthermore, patients should consider the potential costs of managing any side effects or complications that may arise from the treatment. While Tepezza has been found to be generally well-tolerated, there is always the possibility of experiencing adverse reactions that require medical intervention. The cost of managing these side effects can vary widely depending on the severity and type of reaction, ranging from additional doctor visits to hospitalization. Therefore, it is important for patients to have adequate insurance coverage to mitigate these potential costs.
  Considering the above expenses, the total cost of a year's worth of Tepezza treatment can reach upwards of $130,000. This figure can be overwhelming for many patients and is a significant concern, especially for those without comprehensive health insurance coverage. To help alleviate some of this financial burden, Horizon Therapeutics does offer a patient assistance program called HorizonCares, which aims to provide financial assistance to eligible individuals who meet specific criteria.
  It is essential for patients considering Tepezza to have an open and honest discussion with their healthcare providers about the drug's cost and potential financial implications. Exploring options such as financial assistance programs, health insurance coverage, and alternative treatment plans can help individuals make informed decisions about their healthcare.
  In conclusion, while Tepezza(Teprotumumab-trbw) shows promise in treating thyroid eye disease, its cost can be a significant barrier for many patients. With an estimated annual expenditure of over $130,000, it is crucial for individuals to carefully consider the financial implications of this treatment and explore potential avenues for financial assistance. Ultimately, the decision to use Tepezza should be made after a thorough evaluation of its benefits, risks, and financial feasibility in each individual case.